Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioporto ASTHOXF 69 3-Year EPS without NRI Growth Rate is 13.50% as of Jun. 2026, which is 65% above its 10-year median of 8.20. GuruFocus rates THOXF with a GF Score™ of 69/100 and a GF Value™ of $0.15. The stock has 4 warning signs investors should review. Among 161 Medical Diagnostics & Research companies, Bioporto AS ranks better than 54.04% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 13.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 11.30% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -3.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Bioporto AS was 28.60% per year. The lowest was -42.90% per year. And the median was 8.20% per year.
Bioporto AS (OTCPK:THOXF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Bioporto AS 3-Year EPS without NRI Growth Rate Related Terms
THOXF vs TMO, DHR, NTRA: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Bioporto AS's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Bioporto AS's 3-Year EPS without NRI Growth Rate falls into.
Bioporto AS 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 13.50% mean?
Bioporto AS (THOXF) has a 3-Year EPS without NRI Growth Rate of 13.50% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bioporto AS and its competitors. This is 65% above median its historical median of 8.20. According to the industry distribution chart, Bioporto AS ranks #74 out of 161 companies in the Medical Diagnostics & Research industry, placing it in the top 46%.
Is Bioporto AS's 3-Year EPS without NRI Growth Rate too high?
Bioporto AS's current 3-Year EPS without NRI Growth Rate of 13.50% is 65% above median its 10-year median of 8.20. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 10.70. Bioporto AS's value of 13.50% is 26.2% above this industry median. Based on the distribution chart, Bioporto AS ranks #74 out of 161 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bioporto AS has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's 3-Year EPS without NRI Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #74 out of 161 companies for 3-Year EPS without NRI Growth Rate. This puts Bioporto AS in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 10.70. Bioporto AS's value of 13.50% is 26.2% above this benchmark. While the company's 10-year median is 8.20 vs. the industry median of 10.70, Bioporto AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 10.70, based on 161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current 3-Year EPS without NRI Growth Rate of 13.50% is 26.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current 3-Year EPS without NRI Growth Rate is 13.50%, which is 65% above median its own 10-year median of 8.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current 3-Year EPS without NRI Growth Rate of 13.50%. The stock's GF Value™ is $0.15, compared to a current price of $0.15 — trading 0.7% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 13.50%, which is 65% above median its 10-year median of 8.20 and 26.2% above the Medical Diagnostics & Research industry median of 10.70. Bioporto AS's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Bioporto AS (THOXF), the current 3-Year EPS without NRI Growth Rate is 13.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 0.7% below its estimated GF Value™ of $0.15.
Key valuation signals for THOXF:
3-Year EPS without NRI Growth Rate: 13.50% (65% above median its 10-year median of 8.20)
GF Value™: $0.15 vs. price of $0.15 (0.7% below fair value)
Industry Position: 26.2% above the Medical Diagnostics & Research median (#74 of 161)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score
Get the complete analysis for THOXF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
